Clinical Trial: NCT06810609
Immunochemotherapy, Surgery or Chemoradiation, and Durvalumab for Stage IIIA/B NSCLC
Status:
RECRUITINGPhase:
Phase 2| Lead Sponsor: | University Hospital, Bonn |
| Information Provided By: | University Hospital, Bonn |
| Last Update Posted: | 2026-01-27 |
Study Overview
Brief Summary
The hypothesis of the study is that induction immunochemotherapy, followed by surgery or chemoradiation and consolidation Durvalumab immunotherapy, can significantly improve event-free survival in patients with resectable or borderline resectable NSCLC at stage IIIA/B compared to existing treatment methods.
Official Title
Prospective Randomized Phase II Trial on Induction Immunochemotherapy Followed by Surgery or Definitive Chemoradiation and Consolidation Durvalumab (MEDI4736) in Resectable and Borderline Resectable Stage IIIA/B NSCLC
Conditions
Lung Cancer Non-Small Cell Cancer (NSCLC)
Intervention / Treatment
- Procedure: surgery (any volume) and / or pharmaceuticals treatment initiated or planned or only dynamic observation, in accordance with current clinical guidelines
- Radiation: Chemoradiotherapy
- Drug: Immunotherapy
Other Study ID Numbers
- ESR-21-21565
- 2024-516367-80-00
Start Date (Actual)
2025-04-20
Primary Completion Date (Estimated)
2029-12-31
Study Completion Date (Estimated)
2030-09-30
Enrollment (Estimated)
176
Study Type
Interventional
Phase
Phase 2
| Lead Sponsor: | University Hospital, Bonn |
| Information Provided By: | University Hospital, Bonn |
| Last Update Posted: | 2026-01-27 |
Study Overview
Brief Summary
The hypothesis of the study is that induction immunochemotherapy, followed by surgery or chemoradiation and consolidation Durvalumab immunotherapy, can significantly improve event-free survival in patients with resectable or borderline resectable NSCLC at stage IIIA/B compared to existing treatment methods.
Official Title
Prospective Randomized Phase II Trial on Induction Immunochemotherapy Followed by Surgery or Definitive Chemoradiation and Consolidation Durvalumab (MEDI4736) in Resectable and Borderline Resectable Stage IIIA/B NSCLC
Conditions
Lung Cancer Non-Small Cell Cancer (NSCLC)
Intervention / Treatment
- Procedure: surgery (any volume) and / or pharmaceuticals treatment initiated or planned or only dynamic observation, in accordance with current clinical guidelines
- Radiation: Chemoradiotherapy
- Drug: Immunotherapy
Other Study ID Numbers
- ESR-21-21565
- 2024-516367-80-00
Start Date (Actual)
2025-04-20
Primary Completion Date (Estimated)
2029-12-31
Study Completion Date (Estimated)
2030-09-30
Enrollment (Estimated)
176
Study Type
Interventional
Phase
Phase 2